Aerosol-Administered Adelmidrol Attenuates Lung Inflammation in a Murine Model of Acute Lung Injury
Laboratory studyOther animalsWith adelmidrol (a PEA analogue, tested alone)
This study tested palmitoylethanolamide together with adelmidrol (a PEA analogue, tested alone). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Mice with acute lung injury induced by intratracheal lipopolysaccharide at 5 mg/kg
- Dose used in the study
- Adelmidrol 2% by aerosol at 1 and 6 hours after LPS
- Duration
- Hours after LPS instillation; endpoint not stated in the abstract
- What was measured
- Lung damage and airway infiltration; mast cell number and activation markers (chymase, tryptase); oxidative stress and antioxidant enzymes; NF-kB pathway and cytokine release.
What the authors reported
Aerosol adelmidrol reduced LPS-induced lung damage and airway infiltration, reduced mast cell numbers and chymase and tryptase expression, raised antioxidant enzymes, and reduced NF-kB activation and pro-inflammatory cytokines.
Limits of this study
A mouse model of acute lung injury; it cannot show effect in people or animals treated in practice. The senior author is a co-inventor on Epitech Group patents; Epitech makes adelmidrol products.
Source
PubMed 36139146 · doi:10.3390/biom12091308
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.